-
A Tribute to Bernard Lown
There are lessons for us all in the life and legacy of the renowned cardiologist and peace activist Bernard Lown, notes John Mandrola, MD.
Experts And Viewpoints, February 25, 2021
-
Colchicine Post-MI: Close but No Cigar
The inflammatory hypothesis of coronary artery disease has gained traction, but prescribing drugs with anti-inflammatory effects has yet to take off. Could recent data on colchicine change that?
Experts And Viewpoints, February 11, 2021
-
Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF
The pricey drug Entresto is approved for heart failure with reduced ejection fraction, but should it also get an indication for HF with preserved ejection fraction? Cardiologist John Mandrola, MD, says no.
Experts And Viewpoints, January 15, 2021
-
Mandrola's Top 10 in Cardiology for 2020
While the pandemic dominated the medical news, there were both exciting and concerning developments in the world of cardiology.
Experts And Viewpoints, December 15, 2020
-
AHA 2020
EARLY-AF and STOP AF Put Electrophysiology at a Crossroads
Seemingly positive data on earlier use of catheter ablation in patients with atrial fibrillation concerns some electrophysiologists.
Experts And Viewpoints, November 17, 2020
-
AHA 2020
SAMSON Answers the Statin Side Effect Question
A nifty trial presented at the American Heart Association meeting could help patients with statin side effects restart the drugs.
Experts And Viewpoints, November 15, 2020
-
Mandrola Previews AHA 2020
A trial that aims to answer whether statin myalgia is drug related tops the picks. Studies on CT angiography, AF monitoring, fish oils, and a novel MRA will also feature at the 2020 American Heart Association meeting.
Experts And Viewpoints, November 10, 2020
-
Latest EXCEL MI Analysis Settles Nothing; Flaws Remain
A new analysis from the trial comparing stents and surgery in patients with left main coronary artery disease obfuscates and distracts from the core flaws of EXCEL and its interpretation, says John Mandrola, MD.
Experts And Viewpoints, October 01, 2020
-
The PRAETORIAN Trial: Guarded Approach to Subcutaneous ICD Best
Defibrillation without the downsides is the promise of the S-ICD because there are no leads in the veins and heart. But is one RCT enough to trust this technology to prevent sudden cardiac death?
Experts And Viewpoints, September 10, 2020
-
ESC 2020
Seven Quick Thoughts on the New European AF Guidelines
There's much to admire in the new ESC/EACTS guidelines on atrial fibrillation, but the push for opportunistic screening concerns electrophysiologist John Mandrola, MD.
Experts And Viewpoints, September 04, 2020
-
ESC 2020
EAST-AFNET 4 Favors Rhythm Control, but It's Complicated
Electrophysiologist John Mandrola, MD, cautions against oversimplifying the results of EAST-AFNET 4 to mean use more anti-arrhythmic drugs or do more ablation.
Experts And Viewpoints, September 01, 2020
-
ESC 2020
Digoxin Stuns in RATE-AF Trial
A drug with a bad rap in the U.S. outperforms usual practice in patients with permanent AF. Are the results convincing enough to persuade a slow-medicine practitioner like John Mandrola, MD?
Experts And Viewpoints, August 30, 2020
-
Mandrola Previews the Virtual ESC 2020
Trials on SGLT2 inhibitors, rhythm control in AF, and a few drugs he’s never heard of are among John Mandrola’s picks from the upcoming European Society of Cardiology Congress.
Experts And Viewpoints, August 26, 2020
-
LAAO vs DOAC: PRAGUE-17 Falls Short
A comparison of left atrial appendage closure and direct oral anticoagulants for stroke prevention in atrial fibrillation exposes the holes in noninferiority trial design, writes John Mandrola, MD.
Experts And Viewpoints, July 09, 2020
-
Let's Not Move at a Rapid Clip to Repair the Forgotten Valve
Before we expand percutaneous repair of the forgotten valve with the CE-marked TriClip or off-label use of MitraClip, don't forget about the randomized trial, cautions John Mandrola, MD.
Experts And Viewpoints, June 24, 2020
-
Some Data May Be Worse Than No Data in the COVID Era
Over-reaching conclusions from an observational study of anticoagulation in COVID-19 can do more harm than good in our pursuit for scientific truth, argues John Mandrola, MD.
Experts And Viewpoints, May 14, 2020
-
ACC 2020
What If There Is a Virtual ACC and Nobody Cares?
It seems tone-deaf to discuss science-that-can-wait while colleagues across the world fight this challenge, writes John Mandrola, MD, of the upcoming virtual American College of Cardiology Scientific Sessions.
Experts And Viewpoints, March 25, 2020
-
Mandrola's Top 10 Cardiology Stories of 2019
It's probably no surprise that ISCHEMIA and the EXCEL controversy make John Mandrola's annual list for 2019. He also found good news in heart failure and has words of caution for TAVR expansion.
Experts And Viewpoints, December 19, 2019
-
AHA 2019
Signal of Harm From Impella Has an Easy Answer
Two independent observational studies find worse outcomes with the Impella device compared with intra-aortic balloon pump. The time for a randomized controlled trial is now, says John Mandrola, MD.
Experts And Viewpoints, November 19, 2019
-
AHA 2019
The ISCHEMIA Trial -- Cardiology Changes Today
The AHA late-breaking trial comparing an invasive vs medical strategy for patients with stable ischemic disease validates Nobel prize-winning medical conservative Bernard Lown, writes John Mandrola, MD.
Experts And Viewpoints, November 17, 2019
